Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Fig. 1

Swimmer plot and OS and iPFS curve of LM patients with EGFR mutant NSCLC. A Swimmer plot of LM patients with EGFR mutant NSCLC received osimertinib with or without bevacizumab. → means alive, x means dead. B OS of osimertinib plus bevacizumab group and osimertinib group (log-rank test, p = 0.046). C iPFS of osimertinib plus bevacizumab group and osimertinib group (log-rank test, p = 0.037)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us